



Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from the Phase 2b Dry Eye Disease Clinical Trial

September 25, 2018

LEXINGTON, Mass., Sept. 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced it will hold a webcast and conference call on Wednesday, September 26, 2018 at 8:00 a.m. EST to provide the results from its dry eye disease Phase 2b clinical trial.

The dial-in numbers are 1-877-266-8979 for domestic callers and 1-412-317-5231 for international callers. A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

Corporate Contact:

David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcullin@aldeyra.com

Investor Contact:

Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com

Media Contact:

Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
cduong@macbiocom.com

 View original content: <http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-announce-results-from-phase-2b-dry-eye-disease-clinical-trial-300718710.html>

SOURCE Aldeyra Therapeutics, Inc.